For patients with primary progressive multiple sclerosis (PPMS), ocrelizumab is superior for delaying disability progression, ...
Clinical outcome measurement in multiple sclerosis encompasses a spectrum of tools and approaches designed to quantify disease activity, functional impairment and quality of life. Traditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results